Drug · DIN 02446901
ZERBAXA
SINGLE-USE VIALS
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since January 12, 2016; first marketed January 12, 2016.
- Drug Identification Number (DIN)
- 02446901
- Company (DIN owner)
- Merck Canada IncKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Ceftolozane and beta-lactamase inhibitor J01DI54
- Class
- Human
- Record last updated
- August 10, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CEFTOLOZANE (CEFTOLOZANE SULFATE) | 1 G | VIAL |
| TAZOBACTAM (TAZOBACTAM SODIUM) | 0.5 G | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 30, 2015: NOC 17338New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “zerbaxa”. A notice may cover another product or only some lots: read it to see what it covers.
- Zerbaxa (2020-12-16)December 16, 2020 · Drugs · Product safety · Type I